Neus Martínez-Bosch

Prof. Neus Martínez-Bosch

Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2018 in Cancers
Verified
Journal Article
Open access
PDF file
NMNeus Martínez-Bosch
Neus Martínez-Bosch
JVJudith Vinaixa
Judith Vinaixa
Pilar NavarroPilar Navarro
Pilar Navarro
Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, remains one of the most challenging problems for the biomedical and clinical fields, with abysmal survival rates and poor therapy efficiency. Desmoplasia, which is abundant in PDA, can be blamed for much of the mechanisms behind poor drug performance, as it is the main source of the cytokines and chemokines that orchestrate rapid and silent tumor progression to allow tumor cells to be isolated into an extensive fibrotic reaction, which results in inefficient drug delivery. However, since immunotherapy was proclaimed as the breakthrough of the year in 2013, the focus on the stroma of pancreatic cancer has interestingly moved from activated fibroblasts to the immune compartment, trying to understand the immunosuppressive factors that play a part in the strong immune evasion that characterizes PDA. The PDA microenvironment is highly immunosuppressive and is basically composed of T regulatory cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressive cells (MDSCs), which block CD8+ T-cell duties in tumor recognition and clearance. Interestingly, preclinical data have highlighted the importance of this immune evasion as the source of resistance to single checkpoint immunotherapies and cancer vaccines and point at pathways that inhibit the immune attack as a key to solve the therapy puzzle. Here, we will discuss the molecular mechanisms involved in PDA immune escape as well as the state of the art of the PDA immunotherapy.

4 April 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Carlos Alberto OrozcoCarlos Alberto Orozco
Carlos Alberto Orozco
NMNeus Martínez-Bosch
Neus Martínez-Bosch
PGPedro E. Guerrero
Pedro E. Guerrero
JVJudith Vinaixa
Judith Vinaixa
TDTomás Dalotto-Moreno
Tomás Dalotto-Moreno
Pilar NavarroPilar Navarro
Pilar Navarro
Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies. A more comprehensive understanding of the complexity of PDA pathobiology, and especially of the role of the tumor microenvironment in disease progression, should pave the way for therapies to improve patient response rates. In this study, we identify galectin-1 (Gal1), a glycan-binding protein that is highly overexpressed in PDA stroma, as a major driver of pancreatic cancer progression. Genetic deletion of Gal1 in a Kras-driven mouse model of PDA (Ela-KrasG12Vp53−/−) results in a significant increase in survival through mechanisms involving decreased stroma activation, attenuated vascularization, and enhanced T cell infiltration leading to diminished metastasis rates. In a human setting, human pancreatic stellate cells (HPSCs) promote cancer proliferation, migration, and invasion via Gal1-driven pathways. Moreover, in vivo orthotopic coinjection of pancreatic tumor cells with Gal1-depleted HPSCs leads to impaired tumor formation and metastasis in mice. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression. Thus, Gal1 hierarchically regulates different events implicated in PDA biology including tumor cell proliferation, invasion, angiogenesis, inflammation, and metastasis, highlighting the broad therapeutic potential of Gal1-specific inhibitors, either alone or in combination with other therapeutic modalities. Significance Pancreatic ductal adenocarcinoma (PDA) is the third leading of cause of cancer death in the United States and is predicted to be the second one by 2030. The tumor microenvironment is a major source of soluble mediators that influence tumor progression and hinder the success of therapeutic strategies. Using a genetically engineered mouse model and human cell-based systems, we identify galectin-1 (Gal1) as a critical soluble factor capable of regulating tumor–stroma crosstalk promoting proliferation, angiogenesis, and modulation of inflammatory responses, resulting in enhanced tumor development and metastasis. Our data provide an integrated view of the role of Gal1 in the PDA microenvironment and reinforce the high therapeutic value of Gal1 inhibition in PDA treatment.

4 December 2011 in Nature Medicine
Verified
Journal Article
Closed access
EOElena Ortiz-Zapater
Elena Ortiz-Zapater
DPDavid Pineda
David Pineda
NMNeus Martínez-Bosch
Neus Martínez-Bosch
GFGonzalo Fernández-Miranda
Gonzalo Fernández-Miranda
MIMar Iglesias
Mar Iglesias
Pilar NavarroPilar Navarro
Pilar Navarro

30 June 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NMNeus Martínez-Bosch
Neus Martínez-Bosch
MAITE FERNANDEZ-BARRENAMAITE FERNANDEZ-BARRENA
MAITE FERNANDEZ-BARRENA
MMMireia Moreno
Mireia Moreno
EOElena Ortiz-Zapater
Elena Ortiz-Zapater
JMJessica Munné-Collado
Jessica Munné-Collado
Pilar NavarroPilar Navarro
Pilar Navarro
Despite some advances, pancreatic ductal adenocarcinoma (PDAC) remains generally refractory to current treatments. Desmoplastic stroma, a consistent hallmark of PDAC, has emerged as a major source of therapeutic resistance and thus potentially promising targets for improved treatment. The glycan-binding protein galectin-1 (Gal1) is highly expressed in PDAC stroma, but its roles there have not been studied. Here we report functions and molecular pathways of Gal1 that mediate its oncogenic properties in this setting. Genetic ablation of Gal1 in a mouse model of PDAC (EIa-myc mice) dampened tumor progression by inhibiting proliferation, angiogenesis, desmoplasic reaction and by stimulating a tumor-associated immune response, yielding a 20% increase in relative lifesplan. Cellular analyses in vitro and in vivo suggested these effects were mediated through the tumor microenvironment. Importantly, acinar-to-ductal metaplasia, a crucial step for initiation of PDAC, was found to be regulated by Gal1. Mechanistic investigations revealed that Gal1 promoted Hedgehog pathway signaling in PDAC cells and stromal fibroblasts as well as in Ela-myc tumors. Taken together, our findings establish a function for Gal1 in tumor-stroma crosstalk in PDAC and provide a preclinical rationale for Gal1 targeting as a microenvironment-based therapeutic strategy. Cancer Res; 74(13); 3512–24. ©2014 AACR.

1 April 2009 in Gastroenterology
Verified
Journal Article
Open access
PDF file
OROriol Roda
Oriol Roda
EOElena Ortiz–Zapater
Elena Ortiz–Zapater
NMNeus Martínez-Bosch
Neus Martínez-Bosch
Ricardo Gutiérrez-GallegoRicardo Gutiérrez-Gallego
Ricardo Gutiérrez-Gallego
MVMiquel Vila–Perelló
Miquel Vila–Perelló
Pilar NavarroPilar Navarro
Pilar Navarro
Tissue plasminogen activator (tPA) is a multifunctional protein that regulates a broad range of cellular functions, including fibrinolysis, tissue remodeling, and neuronal plasticity.1 x 1 Carmeliet, P., Schoonjans, L., Kieckens, L. et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994; 368: 419–424 Google Scholar See all References , 2 x 2 Collen, D. The plasminogen (fibrinolytic) system. Thromb Haemost. 1999; 82: 259–270 Google Scholar See all References , 3 x 3 Strickland, S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost. 2001; 86: 138–143 Google Scholar See all References 5 Many effects of tPA are mediated by its catalytic activity via plasmin generation. However, tPA also operates as a cytokine that binds to membrane receptors and triggers signaling.4 x 4 Nicole, O., Docagne, F., Ali, C. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001; 7: 59–64 Google Scholar See all References , 5 x 5 Medina, M.G., Ledesma, M.D., Dominguez, J.E. et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J. 2005; 24: 1706–1716 Google Scholar See all References , 6 x 6 Hu, K., Yang, J., Tanaka, S. et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006; 281: 2120–2127 Google Scholar See all References , 7 x 7 Siao, C.J. and Tsirka, S.E. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci. 2002; 22: 3352–3358 Google Scholar See all References , 8 x 8 Diaz, V.M., Hurtado, M., Thomson, T.M. et al. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004; 53: 993–1000 Google Scholar See all References , 9 x 9 Ortiz-Zapater, E., Peiro, S., Roda, O. et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol. 2007; 170: 1573–1584 Google Scholar See all References

1 December 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Pilar NavarroPilar Navarro
Pilar Navarro
NMNeus Martínez-Bosch
Neus Martínez-Bosch
ABAda G. Blidner
Ada G. Blidner
GRGabriel Rabinovich
Gabriel Rabinovich
Galectins are an endogenous family of β-galactoside-binding proteins that play complex and multifaceted roles at various stages of cancer progression, including modulation of tumor cell proliferation, signaling, adhesion, migration, invasion, epithelial–mesenchymal transition, angiogenesis, and immune escape. Recently, galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies. Here, we present an integrated approach to the pleiotropic functions of galectins and discuss their emerging roles with respect to mechanisms of resistance or sensitivity to anticancer therapies. Taken together, these findings suggest that targeting galectins and/or their glycosylated ligands may help to overcome resistance and to increase the clinical efficacy of anticancer strategies.